Source disclosure: February 24, 2026
Welby Inc. [4438.T]
TOKYO, Feb 24 (Pulse News Wire) – Welby Inc. (4438.T) disclosed its fiscal year 2026 (January 1, 2026 to December 31, 2026) revenue forecast during a board meeting held today.
The company expects to achieve a consolidated sales target of ¥1.466 billion, marking a significant shift compared to previous estimates. Welby plans to expand its operations through continued efforts in pharmaceutical client engagements and existing PHR service enhancements. Additionally, the company anticipates growth from newly launched initiatives such as patient-centered medical education platforms and data/research services in primary care areas. These strategies aim to drive revenue growth and contribute to overall expansion.
Regarding operating profit, Welby forecasts a net loss of -¥30 million due to increased investments in organizational strengthening, healthcare provider outreach, and development projects aimed at future growth. Despite anticipated revenue increases, the company expects ongoing expenses related to these strategic investments, leading to projected lower profitability. "Our focus on innovative solutions will position us well for sustained growth." The company acknowledges that actual results could differ based on various factors and emphasizes the importance of continuous investment for long-term success.
AI-translated content. 🟢 Confidence: High See terms • Original filing